Full Press Release Details
MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone®Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at theH.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQto take place on Tuesday, May 19, 2026 in New York.
A live webcast of the fireside chat will be available to conference participants on May 19that 3:00pm ET. The webcast is available to watch bothliveand replay for approximately 90-days following the presentation on the News & Events section of Milestone's websitewww.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference, please contact your H.C. Wainwright representative.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR.